Open Eye

A plain-language record of the U.S. government

117th Congress · House

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

Subjects: Advanced technology and technological innovations · Congressional oversight · Department of Health and Human Services · Drug safety, medical device, and laboratory regulation · Food and Drug Administration (FDA) · Government information and archives · Health programs administration and funding · Health technology, devices, supplies

In plain language

  • House bill in the 117th Congress.
  • Directs the Food and Drug Administration (FDA) to designate qualified colleges (or consortia of such institutions) as National.
  • House passed it on Oct 20, 2021 (substantive).
Official summary (Congressional Research Service)

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021 This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on advanced and continuous pharmaceutical manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

View this measure on congress.gov

Roll-call votes on this measure